"de novo" tıpta yeni, yeniden, ilk kez, kalıtsal olmayan, kendiliğinden anlamlarına gelir.
Burada kastedilen şey, söz konusu hastaların hastalığa ilk kez (yeni) yakalanmış olan hastalardır. Nedeni, kökeni tam olarak bilinmeyen hastalıklar için "Idiopathic" teriminin kullanıldığını göz önüne alacak olursanız, yukarıda verilen açıklamanın kesin doğru olduğu anlaşılır.

--------------------------------------------------
Note added at 2002-11-13 17:38:24 (GMT)
--------------------------------------------------

Tıp sözlüklerindeki \"yeni, yeniden\" karşılıklarını aynen koymanız, anlam kaybına yol açacaktır, çünkü metin içinde \"yeni hasta\" ifadesi ile kastedilen şey belirsizlik taşıyacaktır. Dolayısıyla \"yeni yakalanan\" veya hastalığı \"yeni ortaya çıkan\" ifadesi, cümlenin tam anlamını bulmasını sağlayacaktır.

--------------------------------------------------
Note added at 2002-11-16 14:21:55 (GMT) Post-grading
--------------------------------------------------

\"daha önce tedavi edilmemiş\" demek de mümkün

De novo mutation: A mutation that is not based on family history but occurs when a gene is damaged at conception. ,

de novo - new, not present previously, spontaneous.
de nowo: not familial, not hereditary.

The Latin term \"De novo\" means, in a UK legal context: \"starting afresh.\"

de novo - “Anew.” A trial de novo is a completely new trial.
de novo (L. \"from the beginning, anew\") Arising, anew, afresh, once more. Also ex novo.

de novo: In cancer, the first occurrence of cancer in the body. http://www.phoenix5.org/glossary/de_novo.html

De Novo Lesion - Term used to describe a coronary lesion not previously treated.

Mutational mechanism .In the last few years, detailed analysis of these repeat arrays in de novo and familial FSHD cases by pulsed field gel electrophoresis (PFGE) has contributed significantly to our knowledge on genotype-phenotype relationships and on the genesis of these deletions.

Dopamine agonists. These drugs are valuable adjuncts to LD, but also have the potential to be used as monotherapy in de novo patients. Dopamine agonists (DAs) act directly upon striatal dopamine receptors, and convey their effect without the need to be taken up, chemically transformed, or released by the degenerating nigrostriatal terminals, as does LD.
Thus, there are insufficient data to recommend coronary artery calcium scanning in lieu of stress testing as a broad generalization in patients with chest pain. However, there are sufficient data to suggest that coronary calcium evaluation, especially with EBCT, is ready for clinical application in the de novo patient with chest pain, articularly with an \"atypical\" chest pain presentation, and that this anatomic evaluation may be useful by itself or in addition to exercise testing.

http://www.bloodline.net/stories/storyReader$2354